#Cardiff Lexington Reports First Quarter 2026 Financial Results
Cardiff Lexington Corporation disclosed its financial performance for the first quarter ended March 31, 2026, indicating a notable decline in revenue and a significant increase in operating expenses compared to the same quarter of the previous year.
The company's total revenue for the first quarter of 2026 was reported at $2.2 million, a decrease from $2.9 million in Q1 2025. This drop is attributed primarily to a reduction in surgical procedures over the period.
Gross profit also decreased to $1.3 million, representing 59.3% of total revenue, down from 63.1% in the prior year. Total operating expenses rose to $1.8 million, compared to $1.3 million in the same quarter last year, largely due to share-based compensation totaling $664,000, which was absent in Q1 2025.
Cardiff Lexington recorded a loss from continuing operations of $511,000, or 23.0% of total revenue, contrasting sharply with an income of $544,000, or 18.7% of total revenue, reported in the first quarter of 2025. The overall net loss widened significantly to $3.1 million, compared to $451,000 in the previous year, reflecting increased interest expenses linked to the firm’s credit facilities.
Non-GAAP adjusted EBITDA stood at $164,000, a decline from $546,000 in the first quarter of 2025, marking a challenging performance period for the company.
As of March 31, 2026, Cardiff Lexington's cash stood at $684,000 with total assets increasing by 4.1% to $30.3 million. This demonstrates a strong asset position, despite the operational challenges faced during the quarter.
Alex Cunningham, the CEO, emphasized the company's commitment to expanding its network of Nova Ortho and Spine locations to meet rising patient demands. He expressed optimism about the firm’s growth strategy and its recent upgrade to the OTCQX market, which is expected to enhance its visibility among institutional investors.
The company will host a conference call at 11:00 a.m. Eastern Time on May 19, 2026, offering shareholders and interested parties the opportunity to engage directly with the management team regarding these financial results.
Cardiff Lexington reported total revenue of $2.2 million in Q1 2026, a decrease from $2.9 million in the same period last year. This decline can primarily be attributed to a reduction in surgical procedures, indicating some challenges, yet it also highlights potential areas for future growth.
Total operating expenses increased to $1.8 million in Q1 2026, up from $1.3 million in Q1 2025, largely due to share-based compensation costs. While this rise may concern some investors, it reflects investments in talent and organisational capacity, which can be beneficial for long-term growth.
The recent upgrade to the OTCQX market enhances Cardiff Lexington's visibility and credibility among institutional investors, particularly as it executes on strategic initiatives. This positioning may bolster investor confidence and facilitate better access to working capital in the future.
Interest expenses rose significantly to $1.9 million in the first quarter of 2026, compared to $1.0 million in the previous year. This increase is primarily due to higher fees associated with existing credit arrangements. Understanding this change is vital for evaluating the company's financial health, but it also underlines the ongoing costs of scaling operations.
The net loss for Q1 2026 was $3.1 million, a significant increase from a loss of $451,000 in 2025. Key factors included rising interest expenses and costs associated with share-based compensation. While losses can be concerning, they may reflect strategic investments aimed at future growth.
Cardiff Lexington's total assets increased by 4.1% to $30.3 million as of March 31, 2026, indicating a solid asset base that could support continued growth. This growth in assets, coupled with the company’s efforts to enhance operational efficiency, may be favourable for long-term investors.
The loss from continuing operations totaled $511,000 in Q1 2026, contrasting with a profit of $543,000 in Q1 2025. This shift may raise concerns, but also highlights the transitional nature of businesses as they adapt to changing market conditions, potentially setting the stage for recovery.
Cardiff Lexington is focusing on building a scalable platform within the healthcare sector through organic growth and acquisitions. This strategic direction aligns with their commitment to operational efficiency and capital discipline, suggesting a forward-looking approach that could attract investors seeking long-term value.